Methicillin-resistant *Staphylococcus aureus* (MRSA) animal infection has been reported since the 1970s and is now referred to as livestock-associated MRSA (LA-MRSA). It has only been since 2005, with the studies of MRSA pig-associated strains from sequence type 398, that LA-MRSA started to have greater importance to the medical-scientific community ([@B8]). In Europe and North America, the ST398 remains the most commonly identified type of LA-MRSA ([@B11]; nevertheless, clinical infections by LA-MRSA ST398 are still rare.

In South America, LA-MRSA ST398 has only been associated with porcine carriage in Peru ([@B1]) and milk contamination in Brazil ([@B10]). The epidemiology and public health impact of LA-MRSA in South America remains poorly addressed. Here we present the isolation, phenotypic and genomic characterisation of MRSA ST398/t9538 from a swine presenting exudative epidermitis in Brazil.

The strain SA7112 was isolated in 2012, from a skin swab collected from a 45-day-old swine presenting skin exfoliation with sebaceous exudation and crust formation in Rio Grande do Sul state, Brazil. The skin swab was plated on sheep blood agar (5%) and incubated for 24 h at 37ºC. The hemolytic white colonies were identified as *S. aureus* by polymerase chain reaction (PCR) as described by [@B7]. A single colony was used for: antimicrobial susceptibility profiling, research of *mec*A gene by PCR ([@B7]) and further genome sequencing.

The minimal inhibitory concentration (MIC) was determined by broth microdilution technique ([@B2]) using GPALL1F and BOPO6F Sensititre^®^ Standard Susceptibility MIC Plates (TREK Diagnostic Systems/Thermo Fisher Scientific). *S. aureus* ATCC 29213 was used as quality control. The interpretative breakpoints were obtained in the supplements VET01-S2 ([@B2]) and M100-S24 ([@B3]). SA7112 was resistant to the tested β-lactams with oxacillin MIC \> 4.0 µg/mL confirming the MRSA phenotype. Interestingly, the isolate also presented a vancomycin-intermediate phenotype. SA7112 presented an alarming multirresistant profile with resistance to aminoglycosides, macrolides, tetracyclines, sulfonamides, fluoroquinolones, phenicols, clindamycin, quinupristin/dalfopristin and tiamulin ([Table I](#t1){ref-type="table"}).

TABLE IMinimum inhibitory (MIC) concentration values, antimicrobials testing range and breakpoints applied for SA7112 antimicrobial profilingAntibioticsTesting Range (µg/mL)MIC (µg/mL)MIC BreakpointsSusceptibleIntermediateResistantPenicillin0.12 - 8.0\> 8.0≤ 0.12-≥ 0.25Oxacillin0.25 - 4\> 4.0≤ 2.0-≥ 4.0Ampicillin0.12 - 1616.0≤ 0.25-≥ 0.5Ceftiofur≤ 0.25 - 2.0\> 8.0≤ 2.04.0≥ 8.0Vancomycin0.25 - 168.0≤ 4.08.0 - 16.0≥ 32.0Spectinomycin8.0 - 64.0\> 64.0≤ 32.0-≥ 64.0Streptomycin1000\> 1000\--\> 1000Erythromycin0.25 - 4.0\> 4.0≤ 0.51.0 - 4.0≥ 8.0Tylosin0.5 - 32.0\> 32.0≤ 1.02.0 - 4.0˃ 4.0Tilmicosin4.0 - 64.0\> 64.0≤ 16.0-≥ 32.0Tulathromycin1.0 - 64.0\> 64.0≤ 16.032.0≥ 64.0Tetracycline2.0 - 16.0\> 16.0≤ 4.08.0≥ 16.0Chlortetracycline0.5 - 8.0\> 8.0≤ 0.51.0≥ 2.0Oxytetracycline0.5 - 8.0\> 8.0≤ 0.51.0≥ 2.0Moxifloxacin\*0.25 - 4.0\> 4.0≤ 0.51.0≥ 2.0Levofloxacin\*0.25 - 4.0\> 4.0≤ 1.02.0≥ 4.0Ciprofloxacin\*1 - 2\> 2.0≤ 1.02.0≥ 4.0Danofloxacin0.12 - 1.0\> 1.0≤ 0.25\--Enrofloxacin0.12 - 2.0\> 2.0≤ 0.51.0≥ 2.0Clindamycin0.25 - 16.0\> 16.0≤ 0.51.0 - 2.0≥ 4.0Chloramphenicol2 - 16\> 16.0≤ 8.016.0≥ 32.0Florfenicol0.25 - 8.0\> 8.0≤ 2.04.0≥ 8.0Quinuptn/Dalfoptn\*0.5 - 4\> 4.0≤ 1.02.0≥ 4.0Trimetop/Sulfametx0.5/9.5 - 4/76\> 4/76≤ 2/38-≥ 4/76Sulfadimethoxine256.0\> 256.0≤ 256.0-\>256.0Tiamulin0.5 - 32.0\> 32.0≤ 16.0-≥ 32.0[^1]

Whole genome sequencing was performed through Illumina^®^ Miseq platform with paired-end library. The *de novo* assembly was performed with CLC Main Workbench 7.5.1 (CLC Bio, Denmark) and Geneious 8.0.5 (Biomatters Ltd, Auckland, New Zealand) and resulted in 22 scaffolds with an N~50~ of 466,156. Mapping and ordering of obtained scaffolds with reference strain S0385, an MRSA ST398 (NC_017333), was performed with CLC Microbial Genomics Module (CLC Bio, Denmark) and Mauve multiple genome aligner ([@B4]) and demonstrated the existence of two plasmids pSA7112-1 (KX011076) and pSA7112-2 (KX011077) ([Table II](#t2){ref-type="table"}). The SA7112 draft genome (LNTF00000000.1) comprises \~2.8 Mbp, with an overall G+C content of 32.89%. Automatic genome annotation was performed with NCBI Prokaryotic Genome Annotation Pipeline.

TABLE IIAssembly statistics and basic annotation features of Brazilian livestock-associated methicillin-resistant *Staphylococcus aureus* SA7112 strain chromosome and plasmids ChromosomepSA7112-1pSA7112-2Length2,805,3262,36644,430Scaffolds2011N~50~466,156\--CG%32.8931.0732.80CDS2,660230rRNAs18\--tRNAs59\--

Chromosomal analysis enabled SA7112 typing as SCCmec V(5C2&5) subtype c, *spa* t9538 and ST398. The ST398 has only been reported in one human methicillin- susceptible *S. aureus* (MSSA) Brazilian strain ([@B5] that was further typed as *spa* t034. Even though the identified *spa* t9538 has not been associated with LA-MRSA, it is closely related to t034 that is characterised as a livestock-associated *spa* type. While this is the first report of LA-MRSA ST398 carrying a SCCmec type V(5C2&5) subtype c in Brazil, it has already been established as the predominant LA-MRSA in Europe ([@B9].

The SA7112 genome presents the genes encoding aureolysin (*aur*), beta-hemolysin (*hlb*) and staphylococcal gamma-hemolysins (*hlgA*, *hlgB* and *hlgC*), which are related to bacteria escaping from the host immune system. The *lukM-lukF-PV* (Panton-Valentine bi-component leukotoxin) and the exfoliative toxin genes were not identified. With regard to the resistance profile, only the *fexA*, *norA*, *tetM* and *tetK* resistance genes were detected in SA7112 chromosome while both identified plasmids appear to be mostly responsible for the SA7112 resistance phenotype.

The pSA7112-1 corresponds to an *ermC* plasmid, commonly found in *S. aureus* isolates, while pSA7112-2 comprises a multidrug-resistant plasmid harboring *aadE*, *aadD*, *tetL* and *dfrK* genes. The absence of *van* genes and the multifactorial aspect of vancomycin intermediate resistance indicate the possibility of alterations in the cell wall thickness as responsible for the observed phenotype ([@B6]).

This is the first report of vancomycin-intermediate LA-MRSA ST398/t9538 in Brazil. It highlights the public health risk for dissemination such a multidrug-resistant pathogen, not only to slaughterhouse workers and pig farmers, but also to the community due to the contamination risk of retail pork. There already exists a report of MSSA ST398 in a Brazilian hospital with multi-resistant phenotype ([@B5]). This indicates that the livestock-associated clone (ST398) is already present in Brazilian territory and is underestimated due to the lack of surveillance studies. The identification of vancomycin-intermediate LA-MRSA confirms the existing underrated high risk to public health and, therefore, the necessity to enhance LA-MRSA epidemiological studies in South America.
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[^1]: *\**: applied breakpoints from CLSI document M100-S24 (CLSI 2014).
